Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 22, 2005. The report specifically details changes in director interests regarding American Depositary Shares (ADSs) rather than providing a comprehensive financial performance update.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific executive compensation transaction:
- Transaction Type: Exercise of Stock Appreciation Rights (SARs).
- Director: Dr. L. Shapiro.
- Shares Involved: 615 ADSs.
- Grant Price: $40.5360 per ADS.
- Exercise Date Fair Market Value: $50.91 per ADS.
- Cash Payout: $6,380.01.
Material Changes
The filing reports a material change in the director's interest in the company's ADSs due to the exercise of SARs granted on November 13, 1997. No other material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the disclosure of the director's SAR exercise.
Investor Verification Checklist
- Verify the total number of outstanding ADSs and the impact of this specific exercise on the overall share count.
- Confirm the current fair market value of ADSs to assess the appreciation since the grant date of 1997.
- Review the company's annual report (Form 20-F) for comprehensive financial metrics not included in this 6-K filing.
- Check for any other pending director transactions or changes in equity compensation plans.